Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Acamprosate
Drug ID BADD_D00016
Description Alcohol use disorder is responsible for a large worldwide burden of morbidity, premature mortality, and economic consequences resulting from accidents, violence, incarceration, decreased productivity, and increased healthcare spending.[A229073] Acamprosate, also known by the brand name Campral, is a drug used for the maintenance of alcohol abstinence. It is a structural analogue of the neurotransmitter γ-aminobutyric acid (GABA).[L31758] Acamprosate is the first medication specifically formulated for the maintenance of alcohol abstinence in ethanol-dependent patients after alcohol detoxification[A997], unlike [naltrexone] and [disulfiram]. It was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.[L31783]
Indications and Usage For the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation
Marketing Status Prescription; Discontinued
ATC Code N07BB03
DrugBank ID DB00659
KEGG ID D07058
MeSH ID D000077443
PubChem ID 71158
TTD Drug ID D0GC2M
NDC Product Code Not Available
Synonyms Acamprosate | Acamprostate | N-Acetylhomotaurine | N Acetylhomotaurine | Campral EC | N-Acetylhomotaurine, Magnesium (2:1) Salt | N-Acetylhomotaurine, Monolithium Salt | N Acetylhomotaurine, Monolithium Salt | N-Acetylhomotaurine, Zinc (2:1) Salt | Campral | N-Acetylhomotaurine, Monosodium Salt | N Acetylhomotaurine, Monosodium Salt | Sodium Acetylhomotaurine | Acetylhomotaurine, Sodium | Zulex | Acamprosate Calcium | Calcium Acetylhomotaurine | Acetylhomotaurine, Calcium | Calcium Acetylhomotaurinate | Acetylhomotaurinate, Calcium | N-Acetylhomotaurine, Calcium (2:1) Salt | Calcium Acetyl Homotaurinate | Acetyl Homotaurinate, Calcium | N-Acetylhomotaurine, Monopotassium Salt | N Acetylhomotaurine, Monopotassium Salt | Aotal | Regtect
Chemical Information
Molecular Formula C5H11NO4S
CAS Registry Number 77337-76-9
SMILES CC(=O)NCCCS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Epistaxis22.04.03.001; 24.07.01.005--
Eructation07.01.02.003--
Face oedema08.01.07.003; 10.01.05.002; 23.04.01.004--
Feeling abnormal08.01.09.014--Not Available
Flat affect19.04.01.004--Not Available
Flatulence07.01.04.002--
Fracture12.04.02.001; 15.08.02.001--
Gastric ulcer07.04.03.002--
Gastritis07.08.02.001--
Gastroenteritis07.19.03.001; 11.01.07.004--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.009--Not Available
Gastrointestinal pain07.01.05.005--
Goitre05.02.01.001; 14.11.01.008--Not Available
Gout14.09.01.001; 15.01.06.001--Not Available
Haematemesis07.12.02.002; 24.07.02.011--Not Available
Haematuria20.02.01.006; 24.07.01.047--
Haemoglobin13.01.05.018--Not Available
Hallucination19.10.02.002--
Headache17.14.01.001--
Hepatic cirrhosis09.01.04.001--Not Available
Hepatitis09.01.07.004--Not Available
Hernia08.01.04.001--Not Available
Hostility19.05.01.003--Not Available
Hyperbilirubinaemia01.06.04.003; 09.01.01.003; 14.11.01.010--Not Available
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hyperkinesia17.01.02.008--Not Available
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 7 Pages